Repertoire Immune Medicines signed a major collaboration with Eli Lilly to develop tolerizing therapies for autoimmune diseases, securing up-front and milestone payments that validate the company’s Decode immune‑mapping platform. Financial terms reported include immediate payments and potential development-and-commercial milestones in the multibillion-dollar range, adding to Repertoire’s existing partnerships with Bristol Myers Squibb and Genentech. Repertoire said the deal is the largest to date for its platform and will fund discovery and development of tolerizing vaccine candidates across multiple autoimmune indications. Company leaders highlighted Decode’s ability to identify antigen-specific immune features and generate therapeutic candidates aimed at inducing targeted immune tolerance—an approach that contrasts with broad immunosuppression. The alliance expands big‑pharma interest in antigen‑specific immune modulation and provides Repertoire with capital and validation to accelerate pipeline programs. The partnership also signals continued industry appetite to buy or license platform-driven immunology assets at scale.